Literature DB >> 8104532

bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia.

M Hanada1, D Delia, A Aiello, E Stadtmauer, J C Reed.   

Abstract

The bcl-2 gene becomes transcriptionally deregulated in the majority of low-grade non-Hodgkin lymphomas as a result of t(14;18) translocations that place the bcl-2 gene at 18q21 into juxtaposition with the Ig heavy-chain locus at 14q32. This chromosomal translocation or similar bcl-2 gene rearrangements involving the Ig light-chain genes have been reported to occur in some cases of B-cell chronic lymphocytic leukemia (B-CLL). We analyzed the structure, methylation, and expression of the bcl-2 gene in 20 cases of B-CLL or closely related variants of this lymphoproliferative disorder, including at least 16 typical examples of CD5+ B-CLL. None of the 20 specimens had evidence of bcl-2 gene rearrangements, based on Southern blot analysis using three different bcl-2 probes. However, immunoblot analysis using antibodies specific for the Bcl-2 protein showed that 14 of 20 cases (70%) contained levels of p26-Bcl-2 that were equal to or greater than those found in a t(14;18)-bearing lymphoma cell line. Furthermore, in 19 of 20 cases (95%), the Bcl-2 protein was present at levels that were 1.7- to 25-fold higher than in normal peripheral blood lymphocytes. These differences in the relative levels of Bcl-2 protein among cases of B-CLL appeared to be functionally significant, in that a preliminary analysis of 3 representative cases showed that CLL cells with higher levels of Bcl-2 protein survived longer in culture and were delayed in their onset of DNA degradation relative to CLL cells with lower Bcl-2 protein levels. Evaluation of the methylation status of the bcl-2 gene using the isoschizomers Msp I and Hpa II, and a probe corresponding to the first major exon of the gene showed complete demethylation of both copies of the bcl-2 gene in a region corresponding to a 2.4-kb Msp I fragment in all 20 cases of B-CLL. In contrast, analysis of 6 of 6 B-cell lines that harbor a t(14;18) was consistent with hypomethylation of only one of the two bcl-2 alleles. Neither copy of the bcl-2 gene was demethylated in this region in 5 of 5 lymphoid cell lines that lack this translocation. However, hypomethylation of the bcl-2 gene did not necessarily correlate with the relative levels of Bcl-2 protein present in the B-CLL cells, suggesting that additional mechanisms for regulating bcl-2 expression are involved.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8104532

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  132 in total

1.  DNA methylation patterns in alcoholics and family controls.

Authors:  Manish Thapar; Jonathan Covault; Victor Hesselbrock; Herbert L Bonkovsky
Journal:  World J Gastrointest Oncol       Date:  2012-06-15

2.  Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.

Authors:  Xueqing Liang; E Ashley Moseman; Michael A Farrar; Veronika Bachanova; Daniel J Weisdorf; Bruce R Blazar; Wei Chen
Journal:  Blood       Date:  2010-03-25       Impact factor: 22.113

Review 3.  Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia.

Authors:  Graham Packham; Freda K Stevenson
Journal:  Immunology       Date:  2005-04       Impact factor: 7.397

4.  Karyotypic and molecular abnormalities in chronic lymphocytic leukaemia.

Authors:  C D Fegan; F E Davies
Journal:  Clin Mol Pathol       Date:  1996-08

5.  One-carbon metabolism gene polymorphisms and risk of non-Hodgkin lymphoma in Australia.

Authors:  Kyoung-Mu Lee; Qing Lan; Anne Kricker; Mark P Purdue; Andrew E Grulich; Claire M Vajdic; Jennifer Turner; Denise Whitby; Daehee Kang; Stephen Chanock; Nathaniel Rothman; Bruce K Armstrong
Journal:  Hum Genet       Date:  2007-09-21       Impact factor: 4.132

Review 6.  DNA hypomethylation in the origin and pathogenesis of human diseases.

Authors:  Igor P Pogribny; Frederick A Beland
Journal:  Cell Mol Life Sci       Date:  2009-03-27       Impact factor: 9.261

7.  AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance.

Authors:  Kumudha Balakrishnan; Jan A Burger; William G Wierda; Varsha Gandhi
Journal:  Blood       Date:  2008-10-03       Impact factor: 22.113

Review 8.  Finally, An Apoptosis-Targeting Therapeutic for Cancer.

Authors:  Carlo M Croce; John C Reed
Journal:  Cancer Res       Date:  2016-09-30       Impact factor: 12.701

Review 9.  The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia.

Authors:  Gilad Itchaki; Jennifer R Brown
Journal:  Ther Adv Hematol       Date:  2016-07-08

Review 10.  Redox control of leukemia: from molecular mechanisms to therapeutic opportunities.

Authors:  Mary E Irwin; Nilsa Rivera-Del Valle; Joya Chandra
Journal:  Antioxid Redox Signal       Date:  2012-09-28       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.